Cartalax

Cartalax (AED peptide, T-31) is a synthetic tripeptide consisting of Alanine-Glutamate-Aspartate, developed by Professor Vladimir Khavinson as part of the bioregulatory peptide family. Originally isolated from kidney tissue and found in the alpha-1 chain of type XI collagen, Cartalax has shown potential in supporting cartilage, connective tissue, and cellular regeneration through modulation of proliferation markers and apoptosis pathways.

• Clinical Joint Support
• Preventive Use
• Post-Fracture Recovery

Convenient administration for joint and connective tissue support, used extensively in Russian clinical practice for degenerative conditions with established safety profile.

Each capsule contains 0.1mg (100mcg) of AC-4 peptide complex. Specialized formulation designed to survive digestion and provide systemic bioregulatory effects.

Research protocols from published literature — not dosing recommendations.

• Other Khavinson Peptides — Synergistic: Complementary bioregulatory effects - Cartalax for connective tissue while others target specific organs (Epitalon for pineal, Thymalin for thymus)
• Collagen Supplements — Synergistic: Cartalax may enhance collagen synthesis while oral collagen provides raw materials for tissue repair
• BPC-157 — Compatible: Different mechanisms - BPC-157 for general healing, Cartalax specifically for cartilage/connective tissue
• TB-500 — Compatible: No direct interaction - TB-500 works through actin regulation while Cartalax affects fibroblast proliferation
• Growth Factors (IGF-1, GH) — Monitor Combination: Both affect tissue growth - monitor for excessive proliferation or unexpected tissue changes
• Anti-inflammatory Medications — Compatible: May work well together - Cartalax supports tissue while anti-inflammatories reduce joint inflammation
• Glucosamine/Chondroitin — Synergistic: Complementary joint support - traditional supplements provide building blocks while Cartalax modulates cellular activity
• Immunosuppressants — Unknown: No specific studies on interaction - Cartalax affects cell proliferation, consult physician if on immunosuppressive therapy

Supplies:

• Cartalax capsules (0.1mg each)
• Glass of water
• Food (light meal or snack)

1. 1Take capsules with meals as directed on package
2. 2Each capsule contains 0.1mg (100mcg) of active peptide complex
3. 3Swallow whole with full glass of water
4. 4Do not open or chew capsules
5. 5Store in cool, dry place away from moisture
6. 6Follow official Russian manufacturer instructions for optimal results

Week 1-2: No significant changes, establishing baseline. Week 3-4: Gradual improvement in joint comfort. Month 2: Noticeable mobility improvements. Month 3: Maximum therapeutic effect achieved.

Take with meals as directed by Russian manufacturers to optimize tolerance. No reported side effects in Russian clinical use when taken properly. Well-tolerated even in elderly patients. Can be combined with conventional treatments. No drug dependence reported.

Take with meals as directed by Russian manufacturers to optimize tolerance. No reported side effects in Russian clinical use when taken properly. Well-tolerated even in elderly patients. Can be combined with conventional treatments. No drug dependence reported.

Cartalax should be stored at Room temperature in dry place.